- Trial phase
- Approved
- Time to market
- Already approved and commercially marketed (FDA approval March 2021).
- Why 4/10
- PONVORY is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard, dated catalyst for Vanda is the imsidolimab PDUFA on December 12, 2026, which is a different drug. PONVORY contributes roughly 13% of Vanda's revenue, so its commercial trajectory is not a binary event. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5.
PONVORY itself has no upcoming binary catalyst; the next major Vanda event is the imsidolimab (Quimilza) PDUFA on December 12, 2026 for generalized pustular psoriasis, a separate drug. Watch Q3 2026 earnings (released today, Oct 28) for PONVORY's sales trajectory and any commentary on formulary access or market share trends in the competitive S1P modulator class.
Price Chart
Executive Summary
PONVORY (ponesimod) is an FDA-approved once-daily oral S1P1 receptor modulator for relapsing forms of multiple sclerosis in adults, originally developed by Actelion/Janssen (Johnson & Johnson) and approved in March 2021. Vanda Pharmaceuticals (VNDA) acquired U.S. and Canadian rights in December 2023 for $100M upfront and completed the FDA marketing authorization transfer in 2025. PONVORY generated $27.4M in net product sales for Vanda in FY2025 (roughly 13% of total company revenue), with Q3 2026 sales of $7.7M (up 10% YoY). The drug faces stiff competition from other S1P modulators including generic fingolimod (Gilenya), Mayzent, and Zeposia. With no pending regulatory catalyst for PONVORY itself, Vanda's next major binary event is the imsidolimab PDUFA on December 12, 2026, a separate drug for generalized pustular psoriasis.
How It Works
PONVORY is a once-daily oral pill that works as a selective S1P1 receptor modulator. It traps certain white blood cells (lymphocytes) in lymph nodes, preventing them from entering the bloodstream and reaching the brain and spinal cord, where they would otherwise cause the inflammatory damage that drives multiple sclerosis relapses.
Trial Status
PONVORY was approved by the FDA in March 2021 based on the Phase 3 OPTIMUM study (NCT02425644), which showed it reduced annual relapse rates by nearly a third compared to teriflunomide (Aubagio). The drug is commercially available in the U.S. and Canada under Vanda's commercialization.
The Two-Sided Case
Upcoming Catalysts
- No PONVORY-specific binary catalysts are scheduled. Vanda's next major catalyst is the imsidolimab (Quimilza) PDUFA for generalized pustular psoriasis on December 12, 2026.
- Q3 2026 earnings released today (October 28, 2026) provide the latest PONVORY sales data and 2026 guidance update.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vanda Pharmaceuticals Inc. 8-K VNDA ·Originating report